The Safety and Efficacy of Anakinra, an Interleukin-1 Antagonist in Severe Cases of COVID-19: A Systematic Review and Meta-Analysis

This study aims to assess anakinra's safety and efficacy for treating severe coronavirus disease 2019 (COVID-19). Numerous electronic databases were searched and finally 15 studies with a total of 3,530 patients, 757 in the anakinra arm, 1,685 in the control arm were included. The pooled adjust...

Descripción completa

Detalles Bibliográficos
Autores principales: Somagutta, Manoj Kumar Reddy, Lourdes Pormento, Maria Kezia, Hamid, Pousette, Hamdan, Alaa, Khan, Muhammad Adnan, Desir, Rockeven, Vijayan, Rupalakshmi, Shirke, Saloni, Jeyakumar, Rishan, Dogar, Zeryab, Makkar, Sarabjot Singh, Guntipalli, Prathima, Ngardig, Ngaba Neguemadji, Nagineni, Manasa Sindhura, Paul, Trissa, Luvsannyam, Enkhmaa, Riddick, Chala, Sanchez-Gonzalez, Marcos A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Society of Infectious Diseases; Korean Society for Antimicrobial Therapy; The Korean Society for AIDS 2021
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8258297/
https://www.ncbi.nlm.nih.gov/pubmed/34216117
http://dx.doi.org/10.3947/ic.2021.0016

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8258297/
https://www.ncbi.nlm.nih.gov/pubmed/34216117
http://dx.doi.org/10.3947/ic.2021.0016

Ejemplares similares